



# SANGANI HOSPITALS LIMITED

CIN: U85300GJ2021PLC127189

Registered Office: Sainath Society, Opp. S.T., Keshod - 362220, Junagadh

E-Mail: info@sanganihospitals.com | Phone No. +91 2871 235900

Date: November 14, 2024

To,  
The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block  
Bandra Kurla Complex, Bandra - East  
Mumbai- 400051.

**Sub: Outcome of Board Meeting held on Thursday, November 14, 2024 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Ref.: SANGANI HOSPITALS LIMITED (Symbol: SANGANI)**

Dear Sir,

We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Thursday, November 14, 2024 at Sainath Society, Opp. S. T., KSD T, Village - Keshod, Junagadh Gujarat 362220 at 3.00 p.m. Following matters were decided by the Board:

1. Considered and approved the Unaudited Standalone and consolidated Financial Results of the Company for half year ended September 30, 2024 along with Limited Review Report as per Regulation 33 of SEBI (LODR) Regulations, 2015.

The Board Meeting concluded at 8.45 p.m.


You are requested to take the above on record.

Thanking you.

Yours Faithfully,

For Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

  
Ajay Sangani  
Managing Director  
(DIN: 06718085)

**DIRECTOR**



**Statement of Unaudited Consolidated Financials Results for the Half Year ended on September 30 th,2024**

(Rs. In lakhs)

Sr.No	Particulars	Half year ended on			Year ended on	
		September 30,2024 Unaudited	March 31,2024 Audited	September 30,2023 Unaudited	March 31,2024 Audited	
1	Revenue from Operations	1000.84	766.93	800.69		1567.62
	Other Income	75.98	75.20	9.19		84.39
	<b>Total Revenue (1+2)</b>	<b>1076.82</b>	<b>842.14</b>	<b>809.88</b>		<b>1652.01</b>
2	Expenses:					
	Purchases of Stock in trade	359.84	268.50	302.74		571.24
	Changes in inventories of stock in trade	-36.99	1.93	-20.92		-19.00
	Employee Benefit Expenses	187.82	164.62	155.79		320.41
	Finance costs	0.00	0.00	0.00		0.00
	Depreciation and amortization expenses	17.08	15.82	12.69		28.51
	Other expenses	321.08	198.87	188.70		387.56
	<b>Total expenses</b>	<b>848.83</b>	<b>649.73</b>	<b>638.99</b>		<b>1288.73</b>
3	<b>Profit/(Loss) before tax (3-4)</b>	<b>227.99</b>	<b>192.40</b>	<b>170.89</b>		<b>363.29</b>
4	Tax expense:					
	Current tax	44.95	23.22	44.80		68.01
	Excess/Short Provision for Tax					0.43
	Deferred tax	12.25	3.38	21.78		25.16
	<b>Total tax expenses</b>	<b>57.20</b>	<b>26.60</b>	<b>66.57</b>		<b>93.60</b>
5	<b>Profit/(Loss) for the period (4-5)</b>	<b>170.79</b>	<b>165.81</b>	<b>104.31</b>		<b>269.69</b>
6	Minority Interest	-	-	-		0.36
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>170.79</b>	<b>165.81</b>	<b>104.31</b>		<b>269.68</b>
7	Earnings per share (Face Value of Rs. 10)					
	Basic	1.24	1.20	0.76		1.96
	Diluted	1.24	1.20	0.76		1.96

**Notes:**

- The above results were reviewed and recommended by the Audit Committee, at its meeting held on 14th November,2024, for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- These results have been prepared in accordance with the recognition and measurement principles laid down in AS-25 "Interim Financials Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued thereunder and other accounting principles generally accepted in India.
- The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.
- The Company is engaged in the business of healthcare related services. In the management opinion, this is the only segment and hence there are no separate reportable segment as per AS-17 on Segement Reporting.
- The Company has completed its Initial Public Offering ("IPO") of 37,92,000 new Equity Shares of Rs. 10 each at premium of Rs. 30 each per Equity Shares aggregating to Rs. 1516.80 lakhs. Pursuant to the IPO, the Equity Shares of the Company have got listed on NSE Emerge Platform on August 17, 2023.
- The above consolidated financial result include the result of Subsidiary firm; M/s. Ankur Distributors
- The above financial results are available on the website of the company i.e. www.sanganihospitals.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com
- Figures for previous half year/ year have been regrouped wherever necessary to make them comparable.

For and on behalf of Board of Directors  
Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

Ajay Sangani  
Managing Director  
DIN: 06718085

**DIRECTOR**

Place : Keshod

Date : November 14th, 2024

**Sangani Hospitals Limited**  
Registered Office: Sainath Society, Opp. ST Bus Stand, Keshod, Gujarat -362220  
CIN : U85300GJ2021PLC127189  
Website : www.sanganihospitals.com  
Email: info@sanganihospitals.com  
**Consolidated Statement of Assets and Liabilities as at September 30th,2024**

(Rs. in Lakhs)

Particulars	As at September 30, 2024 Unaudited	As at March 31,2024 Audited
<b>Equity and Liabilities</b>		
<b>Shareholders' funds</b>		
(a) Share Capital	1377.70	1377.70
(b) Reserves and Surplus	2142.16	1971.49
(c) Minority Interest	3.17	3.04
	<b>3523.03</b>	<b>3352.22</b>
<b>Non-current liabilities</b>		
(a) Long term borrowings	8.53	8.53
(b) Deferred tax liabilities(net)	41.72	29.47
(c) Long Term Provisions	3.61	2.82
	<b>53.86</b>	<b>40.81</b>
<b>Current liabilities</b>		
(a) Short term borrowings	-	-
(b) Trade payables	186.81	104.85
(c) Other current liabilities	56.11	42.19
(d) Short term provisions	68.05	0.76
	<b>310.96</b>	<b>147.80</b>
<b>Total - Equity and Liabilities</b>	<b>3887.85</b>	<b>3540.84</b>
<b>Assets</b>		
<b>Non Current Assets</b>		
(a) Property, Plant and Equipments		
(i) Tangible Assets	1320.30	1268.17
(ii) Intangible Assets	-	-
(iii) Capital work in progress	95.39	-
	<b>1415.69</b>	<b>1268.17</b>
(b) Long Term Loans and Advances	16.84	42.63
	<b>1432.53</b>	<b>1310.80</b>
<b>Current Assets</b>		
(a) Inventories	114.37	77.38
(b) Trade receivables	348.20	225.17
(c) Cash and cash equivalents	1977.70	1917.04
(d) Short term loans and advances	-	-
(e) Other Current assets	15.05	10.44
	<b>2455.32</b>	<b>2230.04</b>
<b>Total - Assets</b>	<b>3887.85</b>	<b>3540.84</b>

For and on behalf of Board of Directors  
Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

Ajay Sangani  
Managing Director  
DIN: 06718085

**DIRECTOR**

Place : Keshod  
Date : November 14th, 2024

**Sangani Hospitals Limited**  
Registered Office: Sainath Society, Opp. ST Bus Stand, Keshod, Gujarat -362220  
CIN : U85300GJ2021PLC127189  
Website : www.sanganihospitals.com  
Email: info@sanganihospitals.com

**Consolidated Statement of Cash Flow as at September 30, 2024**

(Rs. in Lakhs)

	As at September 30, 2024 Unaudited	As at March 31, 2024 Audited
<b>Cash flow from operating activities</b>		
<b>Profit/(loss) Before tax</b>	227.99	363.29
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	17.08	28.51
Finance Cost	-	-
<b>Operating profit/(loss) before working capital changes</b>	245.07	391.79
<b>Movements in working capital:</b>		
Increase/(decrease) in short term borrowings	-	-
Increase/(decrease) in trade payables	81.95	27.01
Increase/(decrease) in other current liabilities	13.92	-22.49
Decrease/(increase) in Inventories	-36.99	-19.00
Decrease/(increase) in trade receivables	-123.03	10.60
Decrease/(increase) in short-term loans and advances	-	-
Decrease/(increase) in other Current Assets	-4.60	16.67
<b>Cash generated from Operations</b>	<b>243.60</b>	<b>405.35</b>
<b>Net Cash from Operating Activities (A)</b>	<b>198.65</b>	<b>336.91</b>
<b>Cash flows from investing activities</b>		
Sale/(Purchase) of Fixed Assets	-69.33	-108.80
Increase/(Decrease) in Capital Work in Progress	-95.39	-
Decrease/(increase) in Other Non-current Assets	-	-
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-164.71</b>	<b>-108.80</b>
<b>Cash flow from financing activities</b>		
Acceptance / (Repayment) of Loan		
Increase/(decrease) in other Long Term borrowings	-	-1.55
Increase/(decrease) in long term provision	0.79	1.56
Decrease/(increase) in Long Term Loans and Advances	25.79	-40.16
Increase in share capital	-	379.20
Increase in share premium	-	901.06
Increase In minority Interest	0.13	0.10
<b>Net cash flow from/(used in) financing activities (C)</b>	<b>26.72</b>	<b>1240.20</b>
Net increase/(decrease) in cash and cash equivalents (A+B+C)	60.66	1468.32
Cash and cash equivalents at the beginning of the year	1917.04	448.73
<b>Cash and cash equivalents at the end of the year</b>	<b>1977.70</b>	<b>1917.04</b>

For and on behalf of Board of Directors  
Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

Ajay Sangani  
Managing Director  
DIN: 06718085

*Ajay Sangani*  
**DIRECTOR**

Place : Keshod  
Date : November 14th, 2024



**Offices at CHENNAI- COIMBATORE - MUMBAI -BANGALORE**

---

**Limited Review Report**

Review Report to  
The Board of Directors,  
**Sangani Hospitals Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **Sangani Hospitals Limited** ("the Company") for the half year ended September 30, 2024, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KUMBHAT & CO LLP**

*Chartered Accountants*

Firm Regn. No. S000162/001609S

**Gaurang  
Champaklal  
Unadkat**

Digitally signed by  
Gaurang Champaklal  
Unadkat  
Date: 2024.11.14  
19:47:56 +05'30'

**Gaurang C. Unadkat**

Partner

Mem.No. 131708

UDIN: 24131708BKBKIJK4143

**Place:** Mumbai  
**Dated:** November 14<sup>th</sup>, 2024

**Standalone Financial Results for the period ended September 30,2024**

(Rs.in Lakhs)

Sr.No	Particulars	Half year ended on			Year ended on	
		September 30,2024 Unaudited	March 31,2024 Audited	September 30,2023 Unaudited	March 31,2024 Audited	
1	Revenue from Operations	778.70	625.41	598.16	1223.56	
	Other Income	77.79	72.34	9.19	81.53	
	<b>Total Revenue (1+2)</b>	<b>856.49</b>	<b>697.74</b>	<b>607.35</b>	<b>1305.09</b>	
2	<b>Expenses:</b>					
	Purchases of Stock in trade	134.00	138.49	97.91	236.40	
	Changes in inventories of stock in trade	-26.40	-8.67	-13.84	-22.51	
	Employee Benefit Expenses	186.04	162.88	153.98	316.86	
	Finance costs	-	-	-	-	
	Depreciation and amortization expenses	17.01	15.89	12.51	28.40	
	Other expenses	317.85	194.34	188.39	382.73	
	<b>Total expenses</b>	<b>628.50</b>	<b>502.94</b>	<b>438.94</b>	<b>941.88</b>	
3	<b>Profit/(Loss) before tax (3-4)</b>	<b>227.99</b>	<b>194.81</b>	<b>168.41</b>	<b>363.22</b>	
4	<b>Tax expense:</b>					
	Current tax	44.95	24.01	44.00	68.01	
	Excess/Short Provision for Tax	-	0.43	-	0.43	
	Deferred tax	12.25	3.38	21.78	25.16	
	<b>Total tax expenses</b>	<b>57.20</b>	<b>27.82</b>	<b>65.78</b>	<b>93.60</b>	
5	<b>Profit/(Loss) for the period (5-6)</b>	<b>170.79</b>	<b>166.98</b>	<b>102.63</b>	<b>269.61</b>	
6	<b>Earnings per share (Face Value of Rs. 10)</b>					
	Basic	1.24	1.21	0.74	1.96	
	Diluted	1.24	1.21	0.74	1.96	

**Notes:**

1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on November 14th, 2024 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. These results have been prepared in accordance with the recognition and measurement principles laid down in AS-25 "Interim Financials Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued thereunder and other accounting principles generally accepted in India.

3. The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.

4. The Company is engaged in the business of healthcare related services. In the management opinion, this is the only segment and hence there are no separate reportable segment as per AS-17 on Segement Reporting.

5. The Company has completed its Initial Public Offering ("IPO") of 37,92,000 new Equity Shares of Rs. 10 each at premium of Rs. 30 each per Equity Shares aggregating to Rs. 1516.80 lakhs. Pursuant to the IPO, the Equity Shares of the Company have got listed on NSE Emerge Platform on August 17, 2023.

6. The details of utilization of IPO Proceeds are as per the table set forth below:

S. No.	Particulars	Planned as per Prospectus (Rs. In Lakhs)	Actual Utilization of proceeds upto 30-09-2024 (Rs. In lakhs)	Pending to be utilised (Rs. In Lakhs)
1	Capital Expenditure for expansion in Keshod Hospital	809.58	80.63	728.95
2	Capital Expenditure for expansion in Veraval	319.02	14.76	304.26
3	General Corporate Purpose	161.10	11.86	149.24
4	Issue expenses	227.10	227.1	-
	<b>Total Proceeds from the Issue</b>	<b>1,516.80</b>	<b>334.35</b>	<b>1,182.45</b>

7. The above financial results are available on the website of the company i.e. www.sanganihospitals.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

8. Figures for previous half year/ year have been regrouped wherever necessary to make them comparable.

For and on behalf of Board of Directors  
Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

Ajay Sangani  
Managing Director  
DIN: 06718085

*Ajay Sangani*

**DIRECTOR**

Place : Keshod  
Date : November 14th, 2024

**Standalone Statement of Assets and Liabilities as at September 30, 2024**

Particulars	As at September 30, 2024 Unaudited	As at March 31, 2024 Audited
<b>A. Equity and Liabilities</b>		
<b>1 Shareholders' funds</b>		
(a) Share Capital	1377.70	1377.70
(b) Reserves and Surplus	2142.16	1971.37
	<b>3519.86</b>	<b>3349.07</b>
<b>2 Non-current liabilities</b>		
(a) Long term borrowings	-	-
(b) Deferred tax liabilities(net)	41.72	29.47
(c) Long Term Provisions	3.61	2.82
	45.33	32.29
<b>3 Current liabilities</b>		
(a) Short term borrowings	-	-
(b) Trade payables	144.36	75.03
(c) Other current liabilities	51.57	41.29
(d) Short term provisions	68.05	0.76
	263.97	117.08
<b>Total - Equity and Liabilities</b>	<b>3829.16</b>	<b>3498.44</b>
<b>B. Assets</b>		
<b>1 Non Current Assets</b>		
(a) Property, Plant and Equipments		
(i) Tangible Assets	1319.36	1267.04
(ii) Intangible Assets	-	-
(iii) Capital work in progress	95.39	-
	1414.75	1267.04
(b) Long Term Loans and Advances	16.84	42.63
(c) other non current assets	-	-
	1431.60	1309.68
<b>2 Non-current Investments</b>	86.41	83.81
<b>3 Current Assets</b>		
(a) Inventories	80.03	53.63
(b) Trade receivables	286.12	179.48
(c) Cash and cash equivalents	1934.77	1861.50
(d) Short term loans and advances	-	-
(e) Other Current assets	10.23	10.33
	2311.15	2104.95
<b>Total - Assets</b>	<b>3829.16</b>	<b>3498.44</b>

For and on behalf of Board of Directors

Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

*Ajay Sangani*  
**DIRECTOR**

Ajay Sangani  
Managing Director  
DIN: 06718085

Place : Keshod

Date : November 14th, 2024

**Sangani Hospitals Limited**  
Registered Office: Sainath Society, Opp. ST Bus Stand, Keshod, Gujarat -362220  
CIN : U85300GJ2021PLC127189  
Website : www.sanganihospitals.com  
Email: info@sanganihospitals.com  
**Standalone Cash flow statement For the period ended on September 30, 2024**

Particulars	As at September 30, 2024 Unaudited	As at March 31, 2024 Audited
<b>Cash flow from operating activities</b>		
<b>Profit/(loss) Before tax</b>	227.99	363.22
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	17.01	28.40
Finance Cost	-	-
<b>Operating profit/(loss) before working capital changes</b>	245.00	391.62
<b>Movements in working capital:</b>		
Increase/(decrease) in trade payables	69.33	20.70
Increase/(decrease) in other current liabilities	28.05	-21.44
Increase/(decrease) in short term provision	49.51	0.76
Decrease/(increase) in Inventories	-26.40	-22.51
Decrease/(increase) in trade receivables	-106.65	14.40
Decrease/(increase) in other Current Assets	0.11	16.19
<b>Cash generated from Operations</b>	<b>258.95</b>	<b>399.70</b>
Direct taxes paid	-44.95	-68.44
<b>Net Cash from Operating Activities (A)</b>	<b>214.00</b>	<b>331.26</b>
<b>Cash flows from investing activities</b>		
Sale/(Purchase) of Fixed Assets	-69.33	-108.08
(Increase)/Decrease in Capital WIP	-95.39	0.00
Decrease/(increase) in Other Non-current Assets	-2.60	-2.79
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-167.32</b>	<b>-110.87</b>
<b>Cash flow from financing activities</b>		
Increase/(decrease) in long term provision	0.79	1.56
Decrease/(increase) in Long Term Loans and Advances	25.79	-40.16
Increase in share capital	-	379.20
Increase in share premium	-	901.06
<b>Net cash flow from/(used in) financing activities (C)</b>	<b>26.58</b>	<b>1241.65</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>73.27</b>	<b>1462.05</b>
Cash and cash equivalents at the beginning of the year	1861.50	399.45
<b>Cash and cash equivalents at the end of the year</b>	<b>1934.77</b>	<b>1861.50</b>

For and on behalf of Board of Directors  
Sangani Hospitals Limited

**SANGANI HOSPITALS LIMITED**

Ajay Sangani  
Managing Director  
DIN: 06718085

*Ajay Sangani*  
**DIRECTOR**

Place : Keshod  
Date : November 14th, 2024



**Offices at CHENNAI- COIMBATORE - MUMBAI -BANGALORE**

---

**Limited Review Report**

Review Report to  
The Board of Directors,  
**Sangani Hospitals Limited**

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of **Sanagani Hospitals Limited** ("the Company") for the half year ended September 30, 2024, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KUMBHAT & CO LLP**  
Chartered Accountants

Firm Regn. No. S000162/001609S

Gaurang Champaklal  
Unadkat

Digitally signed by Gaurang  
Champaklal Unadkat  
Date: 2024.11.14 19:48:48  
+05'30'

**Gaurang C. Unadkat**  
Partner

Mem.No. 131708

UDIN: 24131708BKBIIJL9951

**Place:** Mumbai

**Dated:** November 14<sup>th</sup>, 2024